p73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis

Oncogene

Volumn 27, Issue 19, 2008, Pages 2780-2787

  Johnson, J ^a,b   Lagowski, J ^a   Lawson, S ^a   Liu, Y ^a   Kulesz Martin, M ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Keratinocyte; p53 family interplay; p73; Squamous cell carcinoma

Indexed keywords

ISOPROTEIN; PROTEIN MDM2; PROTEIN P63; PROTEIN P73;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CARCINOMA CELL; COMPLEX FORMATION; CONTROLLED STUDY; DNA BINDING; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; IONIZING RADIATION; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANIMALS, NEWBORN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, INBRED BALB C; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; SKIN NEOPLASMS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 42549142975     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210941     Document Type: Article

References (35)

1. Alarcon-Vargas D, Fuchs SY, Deb S, Ronai Z. (2000). p73 transcriptional activity increases upon cooperation between its spliced forms. Oncogene 19: 831-835.
2. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. (2005). p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19: 2122-2137.
3. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. (2005). Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 65: 1918-1924.
4. Cui R, He J, Mei R, de Fromentel CC, Martel-Planche G, Taniere P et al. (2005). Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus. Biochem Biophys Res Commun 336: 339-345.
5. Deyoung MP, Ellisen LW. (2007). p63 and p73 in human cancer: defining the network. Oncogene 26: 5169-5183.
6. Deyoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW. (2006). Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 66: 9362-9368.
7. Dohn M, Zhang S, Chen X. (2001). p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20: 3193-3205.
8. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. (2005). Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363-373.
9. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L. (2002). Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 22: 8659-8668.
10. Goldschneider D, Blanc E, Raguenez G, Haddada H, Benard J, Douc-Rasy S. (2003). When p53 needs p73 to be functional - forced p73 expression induces nuclear accumulation of endogenous p53 protein. Cancer Lett 197: 99-103.
11. Gu J, Nie L, Kawai H, Yuan ZM. (2001). Subcellular distribution of p53 and p73 are differentially regulated by MDM2. Cancer Res 61: 6703-6707.
12. Hofseth LJ, Hussain SP, Harris CC. (2004). p53: 25 years after its discovery. Trends Pharmacol Sci 25: 177-181.
13. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. (2006). MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 281: 33030-33035.
14. Irwin MS, Kaelin Jr WG. (2001). Role of the newer p53 family proteins in malignancy. Apoptosis 6: 17-29.
15. Jin Y, Zeng SX, Dai MS, Yang XJ, Lu H. (2002). MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem 277: 30838-30843.
16. Johnson J, Lagowski J, Sundberg A, Lawson S, Liu Y, Kulesz-Martin M. (2007). p73 loss triggers conversion to squamous cell carcinoma reversible upon reconstitution with TAp73α. Cancer Res 67: 7723-7730.
17. Kadakia M, Slader C, Berberich SJ. (2001). Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol 20: 321-330.
18. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A et al. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809-819.
19. King KE, Ponnamperuma RM, Gerdes MJ, Tokino T, Yamashita T, Baker CC et al. (2006). Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis. Carcinogenesis 27: 53-63.
20. Knights CD, Liu Y, Appella E, Kulesz-Martin M. (2003). Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification. J Biol Chem 278: 52890-52900.
21. Knudson Jr AG. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823.
22. Kulesz-Martin MF, Penetrante R, East CJ. (1988). Benign and malignant tumor stages in a mouse keratinocyte line treated with 7,12-dimethylbenz[a] anthracene in vitro. Carcinogenesis 9: 171-174.
23. Liu G, Chen X. (2005). The C-terminal sterile alpha motif and the extreme C terminus regulate the transcriptional activity of the alpha isoform of p73. J Biol Chem 280: 20111-20119.
24. Liu G, Nozell S, Xiao H, Chen X. (2004a). DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol 24: 487-501.
25. Liu Y, Asch H, Kulesz-Martin MF. (2001). Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting. Cancer Res 61: 5402-5406.
26. Liu Y, Lagowski JP, Vanderbeek GE, Kulesz-Martin MF. (2004b). Facilitated search for specific genomic targets by p53 C-terminal basic DNA binding domain. Cancer Biol Ther 3: 1102-1108.
27. Melino G, De Laurenzi V, Vousden KH. (2002). p73: friend or foe in tumorigenesis. Nat Rev Cancer 2: 605-615.
28. Michael D, Oren M. (2002). The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12: 53-59.
29. Moll UM, Slade N. (2004). p63 and p73: roles in development and tumor formation. Mol Cancer Res 2: 371-386.
30. Parsa R, Yang A, McKeon F, Green H. (1999). Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 113: 1099-1105.
31. Rocco JW, Ellisen LW. (2006). p63 and p73: life and death in squamous cell carcinoma. Cell Cycle 5: 936-940.
32. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
33. Wu Y, Huang H, Miner Z, Kulesz-Martin M. (1997). Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53. Proc Natl Acad Sci USA 94: 8982-8987.
34. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316.
35. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X et al. (1999). MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19: 3257-3266.